Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | CASP2 | P42575 | 1/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | CASP6 | P55212 | 1/20 | 0.53 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CDC25B | P30305 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phthalimide SCHEMBL8421052 | 0.80 | GSK3B (0.65) | GSK3BCASP3CASP2CASP7CASP6 | |
| Phthalimide SCHEMBL28193801 | 0.80 | GSK3B (0.79) | GSK3BCASP3CASP2CASP7CASP6 | |
| Naphthoquinone SCHEMBL6917183 | 0.79 | CDC25B (0.54) | LMNACDC25BSMN1; SMN2KDM4EALDH1A1 | |
| Phthalimide SCHEMBL21409660 | 0.79 | GSK3B (0.62) | GSK3BCASP3CASP2CASP7CASP6 | |
| Phthalimide SCHEMBL28707017 | 0.79 | GSK3B (0.62) | GSK3BCASP3CASP2CASP7CASP6 | |
| Phthalimide SCHEMBL28946377 | 0.78 | GSK3B (0.75) | GSK3BCASP3CASP2CASP7CASP6 | |
| Phthalimide SCHEMBL28253101 | 0.77 | GSK3B (0.94) | GSK3BCASP3CASP2CASP7CASP6 | |
| Phthalimide SCHEMBL5215747 | 0.76 | GSK3B (0.71) | GSK3BCASP3CASP2CASP7CASP6 | |
| Phthalimide SCHEMBL11703668 | 0.76 | GSK3B (0.71) | GSK3BCASP3CASP2CASP7CASP6 | |
| Phthalimide SCHEMBL27955087 | 0.75 | GSK3B (0.79) | GSK3BCASP3CASP2CASP7CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079877-B2 | Process for preparing chiral compounds | PFIZER INC. (US) | 2015-07-14 | — | — | US | disclosed |
| EP-2532660-B1 | Process for preparing chiral compounds | PFIZER PROD INC (US) | 2014-09-10 | — | — | EP | disclosed |
| EP-2185713-B1 | PROCESS FOR PREPARING CHIRAL COMPOUNDS | PFIZER PROD INC (US) | 2014-09-10 | — | — | EP | disclosed |
| US-20140187794-A1 | Process for Preparing Chiral Compounds | PFIZER INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140065407-A1 | MANUFACTURE OF LITHOGRAPHIC PRINTING PLATE PRECURSORS FOR ABLATION IMAGING | KODAK REALTY INC. | 2014-03-06 | — | — | US | disclosed |
| US-8653141-B2 | HIV protease inhibiting compounds | ABBVIE INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8642783-B2 | Process for preparing chiral compounds | PFIZER INC. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2205551-B1 | METHOD OF PRODUCING AMINO DIALKOXY ALDEHYDES VIA HYDROFORMYLATION | REDDY S LAB EU LTD DR (GB) | 2014-01-08 | — | — | EP | disclosed |
| EP-2264032-B1 | HIV PROTEASE INHIBITING SULFONAMIDES | ABBVIE INC (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| WO-2008134327-A1 | METHOD OF PRODUCING AMINO DIALKOXY ALDEHYDES VIA HYDROFORMYLATION | DOW GLOBAL TECHNOLOGIES INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| EP-1709037-A2 | HIV PROTEASE INHIBITING SULFONAMIDES | ABBOTT LABORATORIES (US) | 2006-10-11 | — | — | EP | disclosed |
| EP-1697348-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050159469-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2005-07-21 | — | — | US | disclosed |
| WO-2005061450-A2 | HIV PROTEASE INHIBITING SULFONAMIDES | ABBOTT LABORATORIES (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005061487-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050131042-A1 | HIV protease inhibiting compounds | ABBOTT LABORATORIES | 2005-06-16 | — | — | US | disclosed |
| US-6235731-B1 | REDUCING BLOOD LIPIDS, SUGARS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-0915888-A1 | FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS | Takeda Chemical Industries, Ltd. (JP) | 1999-05-19 | — | — | EP | disclosed |
| WO-1997040051-A1 | FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | SERPINB1, HPN, DNPEP | GSK3B 2369/4885CASP3 244/4885CASP2 466/4885 |
| US-20050159469-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | GSK3B 2369/4885CASP3 244/4885CASP2 466/4885 |
| US-20140187794-A1 | Process for Preparing Chiral Compounds | DERA, ALDOA, DPYD | GSK3B 472/4885CASP3 2850/4885CASP2 2531/4885 |
| US-20050131042-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | GSK3B 2369/4885CASP3 244/4885CASP2 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.